NASDAQ:XBIO Xenetic Biosciences - XBIO Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Xenetic Biosciences Inc Please log in to your account or sign up in order to add this asset to your watchlist. $0.42 +0.03 (+7.65%) (As of 03/27/2023 01:18 PM ET) Add Compare Share Share Today's Range$0.39▼$0.4350-Day Range$0.35▼$0.7352-Week Range$0.24▼$1.25Volume66,576 shsAverage Volume60,138 shsMarket Capitalization$6.40 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Xenetic Biosciences MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside918.1% Upside$4.00 Price TargetShort InterestHealthy0.26% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.19Based on 4 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($0.28) to ($0.39) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.84 out of 5 stars 3.5 Analyst's Opinion Consensus RatingXenetic Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $4.00, Xenetic Biosciences has a forecasted upside of 918.1% from its current price of $0.39.Amount of Analyst CoverageXenetic Biosciences has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.26% of the outstanding shares of Xenetic Biosciences have been sold short.Short Interest Ratio / Days to CoverXenetic Biosciences has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Xenetic Biosciences has recently increased by 58.10%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldXenetic Biosciences does not currently pay a dividend.Dividend GrowthXenetic Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for XBIO. Previous Next 1.8 News and Social Media Coverage News SentimentXenetic Biosciences has a news sentiment score of 0.19. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Xenetic Biosciences this week, compared to 0 articles on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Xenetic Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.50% of the stock of Xenetic Biosciences is held by insiders.Percentage Held by InstitutionsOnly 16.28% of the stock of Xenetic Biosciences is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Xenetic Biosciences are expected to decrease in the coming year, from ($0.28) to ($0.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Xenetic Biosciences is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Xenetic Biosciences is -0.84, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioXenetic Biosciences has a P/B Ratio of 0.29. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Xenetic Biosciences (NASDAQ:XBIO) StockXenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Read More Receive XBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xenetic Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address XBIO Stock News HeadlinesMarch 16, 2023 | finanznachrichten.deJTC Team, LLC: JTC Team to Host Virtual Investor NETs in Cancer Spotlight Event Featuring Xenetic BiosciencesMarch 16, 2023 | finance.yahoo.comJTC Team to Host Virtual Investor NETs in Cancer Spotlight Event Featuring Xenetic BiosciencesMarch 27, 2023 | Oxford Club (Ad)My No. 1 dividend stock for a LIFETIME of income.Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.February 23, 2023 | seekingalpha.comXBIO Xenetic Biosciences, Inc.February 21, 2023 | reuters.comXBIO.PH - | Stock Price & Latest News | ReutersJanuary 17, 2023 | finance.yahoo.comXenetic Biosciences, Inc. Announces Notice of Allowance for Canadian Patent Covering Use of DNase Enzyme for Preventing or Ameliorating Toxicity Associated with ChemotherapyDecember 15, 2022 | finance.yahoo.comWhy We Think Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Is Not Excessive At AllDecember 1, 2022 | finance.yahoo.comThis Is Why Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Looks AppropriateMarch 27, 2023 | Oxford Club (Ad)My No. 1 dividend stock for a LIFETIME of income.Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century! I think it's a crying shame folks don't know how powerful dividends are.November 12, 2022 | finance.yahoo.comXenetic Biosciences Third Quarter 2022 Earnings: Beats ExpectationsSeptember 7, 2022 | finance.yahoo.comXenetic Biosciences, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment ConferenceAugust 12, 2022 | finance.yahoo.comXenetic Biosciences, Inc. Reports Second Quarter 2022 Financial Results and Provides Business UpdateJune 2, 2022 | finance.yahoo.comXenetic Biosciences, Inc. to Participate in the Virtual Investor Innovation in Oncology EventMay 18, 2022 | finance.yahoo.comXenetic Biosciences, Inc. to Present at the H.C. Wainwright Global Investment ConferenceMay 12, 2022 | seekingalpha.comXenetic Biosciences reports Q1 resultsMay 12, 2022 | finance.yahoo.comXenetic Biosciences, Inc. Reports First Quarter 2022 Financial Results and Provides Business UpdateMay 2, 2022 | benzinga.comHC Wainwright & Co. Maintains Buy on Xenetic Biosciences, Lowers Price Target to $4May 2, 2022 | proactiveinvestors.comXenetic Biosciences expands pipeline with DNase based oncology platform from CLS TherapeuticsApril 27, 2022 | seekingalpha.comXenetic stock rises 10% on license deal for CLS Therapeutics' cancer drugs platformApril 27, 2022 | finance.yahoo.comXenetic Biosciences, Inc. Expands Oncology Pipeline with In-Licensing of DNase Based Oncology Platform Comprising Multiple Therapeutic ModalitiesMarch 24, 2022 | morningstar.comXenetic Biosciences, Inc. Reports Full Year 2021 Financial Results and Provides Business Update | MorningstarMarch 23, 2022 | seekingalpha.comXenetic Biosciences GAAP EPS of -$0.55, revenue of $1.16MMarch 23, 2022 | finance.yahoo.comXenetic Biosciences, Inc. Reports Full Year 2021 Financial Results and Provides Business UpdateDecember 11, 2021 | benzinga.com'We are expanding the potential of CAR T cell therapy through the development of our XCART technology platform...' -Tweet From Xenetic BiosciencesNovember 12, 2021 | finance.yahoo.comXenetic Biosciences, Inc. Reports Third Quarter 2021 Financial Results and Provides Business UpdateNovember 4, 2021 | finance.yahoo.comAnalysts Estimate Xenetic Biosciences (XBIO) to Report a Decline in Earnings: What to Look Out forOctober 15, 2021 | msn.comBRIEF-Xenetic Biosciences Amended Agreement With Pharmsynthez To Terminate All Agreement Work OrdersSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive XBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xenetic Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address XBIO Company Calendar Last Earnings11/11/2021Today3/27/2023Next Earnings (Estimated)5/11/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:XBIO CUSIPN/A CIK1534525 Webwww.xeneticbio.com Phone781-778-7720FaxN/AEmployees4Year Founded2011Price Target and Rating Average Stock Price Forecast$4.00 High Stock Price Forecast$4.00 Low Stock Price Forecast$4.00 Forecasted Upside/Downside+920.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.47) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,640,000.00 Net Margins-383.89% Pretax Margin-383.83% Return on Equity-43.49% Return on Assets-40.49% Debt Debt-to-Equity RatioN/A Current Ratio12.72 Quick Ratio13.48 Sales & Book Value Annual Sales$1.71 million Price / Sales3.48 Cash FlowN/A Price / Cash FlowN/A Book Value$1.37 per share Price / Book0.29Miscellaneous Outstanding Shares15,170,000Free Float14,029,000Market Cap$5.95 million OptionableNot Optionable Beta2.77 Social Links Key ExecutivesMr. Jeffrey F. Eisenberg (Age 53)CEO & Director Mr. James F. Parslow (Age 54)CFO, COO & Corp. Sec. Dr. Curtis A. Lockshin (Age 59)Chief Scientific Officer Key CompetitorsIMVNASDAQ:IMVCatalyst BiosciencesNASDAQ:CBIOAileron TherapeuticsNASDAQ:ALRNNeuBase TherapeuticsNASDAQ:NBSEKintara TherapeuticsNASDAQ:KTRAView All CompetitorsInstitutional OwnershipRenaissance Technologies LLCBought 28,300 shares on 2/13/2023Ownership: 0.945%View All Institutional Transactions XBIO Stock - Frequently Asked Questions Should I buy or sell Xenetic Biosciences stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Xenetic Biosciences in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" XBIO shares. View XBIO analyst ratings or view top-rated stocks. What is Xenetic Biosciences' stock price forecast for 2023? 1 analysts have issued 12 month price objectives for Xenetic Biosciences' stock. Their XBIO share price forecasts range from $4.00 to $4.00. On average, they expect the company's share price to reach $4.00 in the next year. This suggests a possible upside of 920.4% from the stock's current price. View analysts price targets for XBIO or view top-rated stocks among Wall Street analysts. How have XBIO shares performed in 2023? Xenetic Biosciences' stock was trading at $0.2851 at the beginning of 2023. Since then, XBIO stock has increased by 37.5% and is now trading at $0.3920. View the best growth stocks for 2023 here. When is Xenetic Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023. View our XBIO earnings forecast. How were Xenetic Biosciences' earnings last quarter? Xenetic Biosciences Inc (NASDAQ:XBIO) announced its quarterly earnings data on Thursday, November, 11th. The company reported ($0.13) earnings per share for the quarter, missing analysts' consensus estimates of ($0.12) by $0.01. The firm earned $0.35 million during the quarter, compared to analysts' expectations of $0.20 million. Xenetic Biosciences had a negative net margin of 383.89% and a negative trailing twelve-month return on equity of 43.49%. What other stocks do shareholders of Xenetic Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Xenetic Biosciences investors own include VBI Vaccines (VBIV), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Biocept (BIOC), Trevena (TRVN), TherapeuticsMD (TXMD), T2 Biosystems (TTOO), Vaxart (VXRT), Aytu BioPharma (AYTU) and Co-Diagnostics (CODX). What is Xenetic Biosciences' stock symbol? Xenetic Biosciences trades on the NASDAQ under the ticker symbol "XBIO." Who are Xenetic Biosciences' major shareholders? Xenetic Biosciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.95%). How do I buy shares of Xenetic Biosciences? Shares of XBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Xenetic Biosciences' stock price today? One share of XBIO stock can currently be purchased for approximately $0.39. How much money does Xenetic Biosciences make? Xenetic Biosciences (NASDAQ:XBIO) has a market capitalization of $5.95 million and generates $1.71 million in revenue each year. The company earns $-5,640,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis. How can I contact Xenetic Biosciences? Xenetic Biosciences' mailing address is 40 Speen Street Suite 102, Framingham MA, 01701. The official website for the company is www.xeneticbio.com. The company can be reached via phone at 781-778-7720 or via email at xbio@jtcir.com. This page (NASDAQ:XBIO) was last updated on 3/27/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.